公开(公告)号：US11617780B2

公开(公告)日：2023-04-04

申请号：US17061146

申请日：2020-10-01

申请人： Sanofi

发明人： Gary J. Nabel ,  Chih-Jen Wei ,  Laura Nguyen ,  Kurt Swanson ,  Te-Hui Chou ,  Stefan Koester

IPC分类号： A61K39/245 ,  A61K39/12 ,  C07K14/05 ,  A61K38/16 ,  A61K47/00

摘要： This disclosure relates to antigenic EBV polypeptides and their use in eliciting antibodies against EBV. Also disclosed are antigenic polypeptides comprising an EBV polypeptide and a ferritin protein.

公开(公告)号：US11590234B2

公开(公告)日：2023-02-28

申请号：US15720542

申请日：2017-09-29

申请人： THE REGENTS OF THE UNIVERSITY OF MICHIGAN

发明人： Peter X. Ma ,  Xiaojin Zhang

IPC分类号： A61K47/00 ,  A61K47/50 ,  A61K47/59 ,  C08G83/00 ,  C08G73/02 ,  C08F210/02 ,  C08G63/66 ,  A61K47/69 ,  A61K47/60 ,  A61L27/18 ,  A61L27/26 ,  A61L27/44 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L27/58 ,  C08G81/00 ,  C12N15/113

摘要： A hyperbranched polymer includes a hyperbranched, hydrophobic molecular core, respective low molecular weight polyethyleneimine chains attached to at least three branches of the hyperbranched, hydrophobic molecular core, and respective polyethylene glycol chains attached to at least two other branches of the hyperbranched, hydrophobic molecular core. Examples of the hyperbranched polymer may be used to form hyperbranched polyplexes, and may be included in DNA or RNA delivery systems.

公开(公告)号：US11590198B2

公开(公告)日：2023-02-28

申请号：US17026543

申请日：2020-09-21

申请人： UNIVERSITAT AUTONOMA DE BARCELONA ,  INSTITUT RECERCA HOSPITAL DE LA SANTA CREU I SANT PAU ,  CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER BBN)

发明人： Antonio Pedro Villaverde Corrales ,  Esther Vazquez Gomez ,  Maria Virtudes Cespedes Navarro ,  Isolda Casanova Rigat ,  Neus Ferrer Miralles ,  Ramon Mangues Bafalluy ,  Ugutz Unzueta Elorza

IPC分类号： A61K38/10 ,  A61K47/62 ,  A61K47/66 ,  A61K47/00 ,  C07K7/08 ,  C07K14/00 ,  C12N15/62 ,  A61P31/14 ,  A61P35/00 ,  C07K14/435

摘要： Conjugates comprising a targeting moiety specific for the CXCR4 and based on the polyphemusin-derived peptide and a therapeutic or imaging agent are provided. Therapeutic and diagnostic methods with the conjugates which require specific targeting to CXCR4+cells are provided as well.

公开(公告)号：US20220340911A1

公开(公告)日：2022-10-27

申请号：US17634708

申请日：2020-08-13

申请人： AMGEN INC.

发明人： Wei GU ,  Essa Hu HARRINGTON ,  Oliver HOMANN

IPC分类号： C12N15/113 ,  C12N15/10 ,  A61K47/00

摘要： The present invention relates to RNAi constructs for reducing expression of the SLC30A8 gene. Methods of using such RNAi constructs to treat or prevent disease, such as pre-diabetes or diabetes are also described.

公开(公告)号：US20220170019A1

公开(公告)日：2022-06-02

申请号：US17599463

申请日：2020-02-14

申请人： SERVICIO ANDALUZ DE SALUD ,  UNIVERSIDAD DE MÁLAGA ,  UNIVERSIDAD DE SEVILLA ,  CIBER

发明人： Said LHAMYANI ,  Adriana MARIEL GENTILE ,  Francisco José TINAHONES MADUEÑO ,  Rajaa EL BEKAY RIZKY ,  Rosa María GIRÁLDEZ PÉREZ ,  Elia María GRUESO MOLINA ,  Mª Pilar PÉREZ TEJEDA

IPC分类号： C12N15/113 ,  A61K31/7105 ,  A61K47/00 ,  B82Y5/00

摘要： The present invention relates to compositions, methods and uses, consisting of a functionalised miRNA-based nanosystem for treating obesity, weight loss and/or reduction of localised fat, which comprises miR-21 or other derived or equivalent compounds such as modified polynucleotides, synthetic mimetic and/or isomiR of miR-21; and a carrier which comprises an optimised nanoparticle for effectively binding oligonucleotides, forming an adequate nanosystem for in vivo transfection and, in particular, for the in vivo release of genes in fatty tissue.

公开(公告)号：US11219690B2

公开(公告)日：2022-01-11

申请号：US15103482

申请日：2014-12-15

申请人： Novo Nordisk Health Care AG

发明人： Charlotte Schou Hunneche ,  Thomas Budde Hansen ,  Ernst Broberg Hansen

IPC分类号： A61K47/54 ,  C07K1/107 ,  A61K47/00

摘要： The invention relates to methods for obtaining a protein conjugate wherein a cysteine residue of the protein serves as attachment point for the chemical moiety conjugated to the protein.

公开(公告)号：US11202837B2

公开(公告)日：2021-12-21

申请号：US15513393

申请日：2015-09-25

申请人： Antikor Biopharma Limited

发明人： Mahendra Persaud Deonarain ,  Gokhan Yahioglu ,  Ioanna Stamati ,  Savvas Saouros ,  Prashant Bhimrao Kapadnis

IPC分类号： A61K47/64 ,  A61K47/68 ,  A61K47/00 ,  C07K16/00

摘要： The invention provides compounds comprising a therapeutic agent coupled to a carrier molecule, with a minimum coupling ratio of 5:1; wherein the carrier molecule is (i) an antibody fragment or derivative thereof or (ii) an antibody mimetic or derivative thereof; and wherein the therapeutic agents are coupled onto a lysine amino acid residue; and further wherein the therapeutic agent is not a photosensitising agent. There is also provided uses, methods relating to such compounds, as well as processes for their manufacture.

公开(公告)号：US11197924B2

公开(公告)日：2021-12-14

申请号：US16844763

申请日：2020-04-09

申请人： Beijing Boxin Nature Biotech Ltd.

发明人： Miao Jiang ,  Hao Wu

IPC分类号： A61K48/00 ,  A61K47/00 ,  A61K9/127 ,  C07K14/47 ,  C12N15/85 ,  A61K39/12 ,  A61P31/18 ,  A61K41/10 ,  A61L2/00 ,  A61K39/00

摘要： Disclosed herein is a photochemical preparation method of an autologous plasma inactivated vaccine for the treatment of acquired immune deficiency syndrome (AIDS), including the following steps: drawing autologous blood from an AIDS patient to form blood to be treated; separating the blood to obtain plasma to be treated; adding a photosensitizer into the plasma to be treated to form plasma to be inactivated; and subjecting the plasma to be inactivated to photochemical inactivation to obtain the autologous plasma inactivated vaccine.

公开(公告)号：US11104638B2

公开(公告)日：2021-08-31

申请号：US16327283

申请日：2017-07-20

申请人： DAICEL CORPORATION ,  YAMAGUCHI UNIVERSITY

发明人： Yuichi Sakanishi ,  Takashi Saeki ,  Aya Kaide

IPC分类号： A61K9/00 ,  A61K47/00 ,  C07C233/65 ,  A61K8/42 ,  A61K47/18

摘要： Provided is a thickening/stabilizing agent that thickens, gelatinizes, and/or stabilizes a fluid organic substance to a desired viscosity. The thickening/stabilizing agent according to the present invention contains a compound (1) represented by Formula (i) and a compound (2) represented by Formula (ii), in a mole ratio of the compound (1) to the compound (2) of 95:5 to 25:75. The four R1s in Formula (i) represent, identically in each occurrence, a C12-C18 aliphatic hydrocarbon group; and the four R2s in Formula (ii) represent, identically in each occurrence, an C4-C10 aliphatic hydrocarbon group. Formulae (i) and (ii) are expressed as follows:

公开(公告)号：US11066355B2

公开(公告)日：2021-07-20

申请号：US17025779

申请日：2020-09-18

申请人： ModernaTX, Inc.

发明人： Kerry E. Benenato ,  Mark Cornebise ,  Edward Hennessy ,  Ellalahewage S. Kumarasinghe

IPC分类号： C07C229/00 ,  A61K47/00 ,  A61K9/00 ,  C07C229/24 ,  A61K48/00 ,  A61K31/713 ,  A61K9/127 ,  A61K47/54

摘要： The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.